CA-NTTVC
26.10.2020 12:42:10 CET | Business Wire | Press release
NTTVC today publicly announced its $500 million fund to help startups reach rapid global scale by harnessing the power of partnership. The independent venture capital firm was founded by entrepreneur and investor Vab Goel in collaboration with global technology service provider NTT . The firm is also announcing investments in five startups delivering impactful innovations for businesses and consumers: Celona , Eko , nference , Shoreline and UDP Labs .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005262/en/
NTTVC invests broadly across all stages and sectors, with an emphasis on the future of enterprise, digital health and innovations powered by AI, machine learning and data. By combining the deep relationships of its investment team with the reach of NTT, the firm offers access to a robust network of industry experts, customers, entrepreneurs, business leaders, system integrators and service providers who can help startups make better decisions, more quickly.
NTT is a $109 billion, top five global technology service provider serving 75 million mobile subscribers, 3 million businesses and 120,000 enterprise customers with a local presence in over 80 countries. The company has a long history of embracing startups and helping them achieve global scale. By partnering with Goel to form a returns-driven venture capital fund, NTT deepens its commitment to building long-term relationships in the entrepreneurial ecosystem. In turn, NTTVC portfolio companies have the choice and opportunity to sell to, through and with NTT to help scale their businesses.
“Our mission is to use technology for good to solve social challenges for people, clients and communities,” said Jun Sawada, President and CEO of NTT Corporation. “We have always believed that the startup ecosystem is essential to delivering on that promise, which is why we chose to partner with NTTVC to fuel the next generation of world-changing technologies.”
Collectively, the NTTVC team has founded, advised, scaled and invested in over a hundred startups. Their drive for supporting entrepreneurs stems from their direct experiences as founders and venture capitalists. Prior to founding NTTVC, Goel was a Partner at Norwest Venture Partners for 19 years and helped build many of the foundational technologies of today’s Internet as an entrepreneur, venture capitalist and technologist. Partner Fay Hazaveh Costa worked closely with Goel at Norwest Venture Partners and previously helped launch Hewlett Packard Enterprise’s venture group. Mike Koenig, Portfolio Development Partner, is a seasoned sales and business development leader who was an early executive at two startups backed by Goel. Koenig supports NTTVC portfolio companies through impactful connections with the firm’s network.
“We are still in the early innings of a digital transformation that is affecting every industry and creating unprecedented opportunities for startups,” said Vab Goel. “We are passionate about teaming up with entrepreneurs through every phase of their journey to build impactful companies.”
“NTTVC offers entrepreneurs the best of both worlds: an independent and agile investment model coupled with the unique access to our global network,” said Fay Hazaveh Costa. “This powerful combination gives startups a true competitive advantage in scaling and realizing their vision.”
For more information read the firm’s blog post and visit nttvc.com .
About NTTVC
NTTVC is an independent venture capital firm formed in collaboration with NTT. Leveraging a unique partnership-focused strategy and deep industry network, NTTVC unlocks doors to relationships that can help startups reach global scale. With its $500M inaugural fund, the firm invests broadly in technology startups of all stages and sectors, with an emphasis on the future of enterprise, digital health and innovations powered by AI, machine learning and data. NTTVC is headquartered in Silicon Valley. Learn more at nttvc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005262/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom